USA Financial Formulas Acquires Shares of 1,738 Axon Enterprise, Inc. (NASDAQ:AXON)

USA Financial Formulas bought a new stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 1,738 shares of the biotechnology company’s stock, valued at approximately $1,033,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Quent Capital LLC raised its stake in shares of Axon Enterprise by 1,875.0% during the third quarter. Quent Capital LLC now owns 79 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 75 shares in the last quarter. Prestige Wealth Management Group LLC increased its holdings in Axon Enterprise by 115.8% during the 3rd quarter. Prestige Wealth Management Group LLC now owns 82 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 44 shares during the period. Brooklyn Investment Group purchased a new position in Axon Enterprise during the 3rd quarter worth $41,000. Planning Capital Management Corp raised its position in Axon Enterprise by 83.3% during the 3rd quarter. Planning Capital Management Corp now owns 121 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 55 shares in the last quarter. Finally, Friedenthal Financial purchased a new stake in shares of Axon Enterprise in the 3rd quarter worth $51,000. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Axon Enterprise Price Performance

Shares of AXON opened at $580.00 on Thursday. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.96 and a quick ratio of 2.63. The company’s fifty day moving average price is $615.21 and its 200-day moving average price is $455.82. Axon Enterprise, Inc. has a 1-year low of $246.99 and a 1-year high of $698.67. The firm has a market capitalization of $44.23 billion, a PE ratio of 149.87, a price-to-earnings-growth ratio of 5.71 and a beta of 1.04.

Insider Buying and Selling at Axon Enterprise

In other Axon Enterprise news, Director Julie A. Cullivan sold 1,261 shares of the business’s stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $682.06, for a total value of $860,077.66. Following the completion of the transaction, the director now directly owns 2,392 shares of the company’s stock, valued at approximately $1,631,487.52. The trade was a 34.52 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Michael Garnreiter sold 1,000 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $639.69, for a total transaction of $639,690.00. Following the sale, the director now directly owns 24,259 shares in the company, valued at $15,518,239.71. The trade was a 3.96 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 50,545 shares of company stock worth $30,721,337. 5.70% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. JMP Securities raised their price target on Axon Enterprise from $430.00 to $500.00 and gave the company a “market outperform” rating in a research note on Thursday, October 31st. Needham & Company LLC raised their target price on shares of Axon Enterprise from $525.00 to $600.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Northland Securities upped their price target on shares of Axon Enterprise from $365.00 to $550.00 and gave the stock an “outperform” rating in a research report on Monday, November 11th. Robert W. Baird lifted their price objective on shares of Axon Enterprise from $600.00 to $800.00 and gave the company an “outperform” rating in a report on Friday, December 6th. Finally, TD Cowen initiated coverage on Axon Enterprise in a report on Wednesday, January 8th. They set a “buy” rating and a $700.00 target price for the company. One investment analyst has rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $504.92.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.